What's breaking now, across thousands of outlets.
Vertex dominates cystic fibrosis and has a debt-free balance sheet, but can its pipeline restore faster growth? See why our analysts gave the stock a strong 7.3 out of 10.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
Kyrish's acquisition boosts his direct stake by 9% to 29,114 shares, signaling confidence in the chemical maker despite its recent $1.2 billion net loss.
Key PointsAcquisition of ~500,000 shares at $4.39 per share resulted in a total investment of ~$2.2 million as of August 14, 2026.
Vanadium revenue jumped 68.5% on higher sales and pricing, plus a major U.S. Defense order.
The USD/CHF advanced on Friday, registering a modest 0.07% gain, trading at 0.8010. During the week, the pair finished with losses of over 1.49%, triggered by a drop in US yields on Wednesday, as the…
